Owen Adams Catherine 4

What Happened

• ACADIA Pharmaceuticals CEO Catherine Owen Adams received two equity awards on March 6, 2026: a grant of 263,005 derivative shares (stock option) and 76,509 restricted stock units (RSUs). Both are reported as acquisitions at $0.00 (transaction code A = award/grant), so no cash was paid for these grants in the filing.

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (timely — filed within the two-business-day window).
• Reported amounts: 263,005 (derivative option-type award) and 76,509 (restricted stock units); total 339,514 shares awarded; acquisition price shown as $0.00 because these are compensation grants.
• Vesting/terms noted in footnotes:
  • F1: The stock option award vests 25% on March 6, 2027, then the remainder vests in 36 equal monthly installments thereafter.
  • F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F3: The RSUs vest in four equal annual installments beginning March 6, 2027.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Code: A = Award/Grant (derivative instruments); no sale or open-market purchase reported.

Context

• These are compensation grants, not open-market purchases or sales. The awards are subject to future vesting, so they do not represent immediately tradable shares. For retail investors, such grants are routine executive compensation and should be interpreted as part of long-term incentive pay rather than a direct bullish or bearish trading signal.